Update on Antithrombotic Therapy after Percutaneous Coronary Intervention

Area of Science:

• Cardiology
• Pharmacology
• Interventional Cardiology

Background:

• Percutaneous coronary intervention (PCI) is standard for angina and acute coronary syndrome.
• Antithrombotic therapy is essential post-PCI to prevent ischemic events.
• Dual antiplatelet therapy (DAPT) with aspirin and a P2Y12 inhibitor reduces stent thrombosis.

Purpose of the Study:

• To review current evidence on antithrombotic therapy in patients with coronary artery disease undergoing PCI.
• To address controversies regarding DAPT duration and agent choice.
• To discuss challenges of combined oral anticoagulation and antiplatelet therapy.

Main Methods:

• Literature review of current evidence.
• Analysis of studies on antithrombotic regimens post-PCI.
• Synthesis of data on balancing thrombotic and bleeding risks.

Main Results:

• DAPT decreases stent-related thrombotic risks but optimal strategies remain debated.
• Choice of P2Y12 inhibitor and therapy duration are controversial.
• Integrating oral anticoagulation with antiplatelet therapy presents complex clinical challenges.

Conclusions:

• Optimal antithrombotic regimen post-PCI requires balancing efficacy and safety.
• Further research is needed to clarify optimal duration and agent selection for DAPT.
• Careful consideration of bleeding risk is paramount when combining anticoagulation and antiplatelet therapy.